AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7257029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31806614 — intervention group
Group type: EXPERIMENTAL
Intervention: TALI Train (intervention group)
Number of subjects: 80
Study 31806614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 30106963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented morphine analgesia (0.5 mg/ml morphine plus 2 μg/ml dexmedetomidine in 100 ml normal saline)
Number of subjects: 58
Study 30106963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented morphine analgesia
Number of subjects: 58
Study 30106963 — intervention group
Group type: COMPARATOR
Intervention: Morphine analgesia
Number of subjects: 58
Study 26345103 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF with oblique interdental incisions (OBL technique)
Number of subjects: 10
Study 26345103 — intervention group
Group type: COMPARATOR
Intervention: CAF with horizontal interdental incisions (HOR technique)
Number of subjects: 10
Study 25011433 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 24
Study 25011433 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional exercises and static volar wrist-hand orthosis)
Number of subjects: 24
Study 22526864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol
Number of subjects: 36
Study 22526864 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal tulobuterol patch
Number of subjects: 36
Study 22526864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol and transdermal tulobuterol patch
Number of subjects: 36
Study 20500876 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline with 6% poly (O‐2‐hydroxyethyl) starch solution (HH)
Number of subjects: 19
Study 20500876 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy (Ringer's Acetate and saline 9 mg/ml) (control)
Number of subjects: 19
Study 20500876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 20500876 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 19
Study 18382668 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 MBq (30 mCi) of radioiodine (131I)
Number of subjects: 160
Study 18382668 — intervention group
Group type: EXPERIMENTAL
Intervention: 3700 MBq (100 mCi) of radioiodine (131I)
Number of subjects: 160
Study 16339664 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670, a once-daily oral iron chelator
Number of subjects: 264
Study 12550812 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic anterior cruciate ligament deficient subjects prior to surgery
Number of subjects: 20
Study 12550812 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic anterior cruciate ligament deficient subjects following surgery
Number of subjects: 20
Study 12550812 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 10778276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive stimulation with failure on a bogus intelligence test
Number of subjects: 40
Study 10778276 — intervention group
Group type: COMPARATOR
Intervention: Nonaversive stimulation with failure on a bogus intelligence test
Number of subjects: 40
Study 10778276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive stimulation with success on a bogus intelligence test
Number of subjects: 40
Study 10778276 — intervention group
Group type: COMPARATOR
Intervention: Nonaversive stimulation with success on a bogus intelligence test
Number of subjects: 40
Study 9165691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous proton pump inhibitors (80 mg pantoprazole or omeprazole bolus followed by 8 mg/hour continuous infusion)
Number of subjects: 0
Study 9165691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1642186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 40 mg/day)
Number of subjects: 243
Study 1642186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 6133546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 6
Study 31006300 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care and selective medical management
Number of subjects: 294
Study 31006300 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 294
Study 29627940 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor rehabilitation (4-week neurorehabilitation)
Number of subjects: 29
Study 26924419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 0
Study 26924419 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 24149241 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization of the left hand for 24 hours (experimental group)
Number of subjects: 0
Study 24149241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immobilization)
Number of subjects: 0
Study 23672109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Paracetamol 1g diluted to 20 mls with normal saline
Number of subjects: 56
Study 23672109 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline 20 mls
Number of subjects: 56
Study 19582757 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized functional enhancement program (FEP)
Number of subjects: 74
Study 19582757 — intervention group
Group type: COMPARATOR
Intervention: General occupational therapy (Control)
Number of subjects: 74
Study 17599439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 2769
Study 17599439 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 2769
Study 16128356 — intervention group
Group type: EXPERIMENTAL
Intervention: RDC/TMD examination protocol
Number of subjects: 24
Study 12103382 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal-dose dopamine infusion (3 microg kg(‐1) min(‐1)) for 48 hours
Number of subjects: 50
Study 12103382 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 50
Study 10408031 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S) 40 mg daily
Number of subjects: 254
Study 10408031 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 254
Study 10408031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 254
Study 7970425 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastron (89Sr-chloride)
Number of subjects: 29
Study 7970425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3555578 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (2 mg once daily)
Number of subjects: 16
Study 3555578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29526608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day)
Number of subjects: 25874
Study 29526608 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (1g/day)
Number of subjects: 25874
Study 29526608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D among African-Americans (at-risk group)
Number of subjects: 25874
Study 29526608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents among participants with high-risk factors or sub-syndromal depression
Number of subjects: 25874
Study 29526608 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline nutrient levels
Number of subjects: 25874
Study 29526608 — intervention group
Group type: EXPERIMENTAL
Intervention: Key biomarkers and factors from pre-randomization blood samples
Number of subjects: 25874
Study 26242380 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP) 50-300 mg subcutaneous and 200-400 mg intravenous doses
Number of subjects: 95
Study 26242380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 25399229 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m(2))
Number of subjects: 481
Study 25399229 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m(2))
Number of subjects: 481
Study 25399229 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 481
Study 25399229 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 481
Study 22672447 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary anastomosis (PRA)
Number of subjects: 90
Study 22672447 — intervention group
Group type: COMPARATOR
Intervention: Nonrestorative colon resection
Number of subjects: 90
Study 20142302 — intervention group
Group type: COMPARATOR
Intervention: THC
Number of subjects: 35
Study 20142302 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 35
Study 20142302 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol + THC
Number of subjects: 35
Study 20142302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18515519 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (active), four or more courses
Number of subjects: 205
Study 18515519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 15747272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 50 mg, 1 hour before surgery
Number of subjects: 60
Study 15747272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12593019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of prostate (TUVP)
Number of subjects: 206
Study 12593019 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 206
Study 10371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin, 5 mg/kg over 60 min, max dose 500 mg (Group I)
Number of subjects: 22
Study 10371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin dosed according to a formula for desired peak concentration of 14 mg/L (Group II)
Number of subjects: 22
Study 8873731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass at 37 degrees C
Number of subjects: 96
Study 8873731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass at 32 degrees C
Number of subjects: 96
Study 8873731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass at 28 degrees C
Number of subjects: 96
Study 1744909 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study 1744909 — intervention group
Group type: COMPARATOR
Intervention: Hygiene alone
Number of subjects: 0
Study 6852098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (100 mg)
Number of subjects: 15
Study 6852098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (100 mg); Naloxone (8 mg)
Number of subjects: 15
Study 6852098 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (32 mg)
Number of subjects: 15
Study 6852098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6852098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (100 mg); Naloxone (32 mg)
Number of subjects: 15
Study 6852098 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 15
Study 31703120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 1312
Study 31703120 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 g/d)
Number of subjects: 1312
Study 31703120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both vitamin D3 and omega-3)
Number of subjects: 1312
Study 27844124 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment program
Number of subjects: 155
Study 27844124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 24306109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone area measurement in OA participants
Number of subjects: 2197
Study 24306109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone area change
Number of subjects: 2197
Study 24306109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage thickness measure (cMFTC)
Number of subjects: 2197
Study 24306109 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint space width (JSW)
Number of subjects: 2197
Study 24306109 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index, gender, and alignment
Number of subjects: 2197
Study 24141882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepuncture ultrasound examination in lean parturients (group 1, n=25)
Number of subjects: 100
Study 24141882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepuncture ultrasound examination in obese parturients (group 2, n=25)
Number of subjects: 100
Study 24141882 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique in obese parturients (group 4, n=25)
Number of subjects: 100
Study 24141882 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique in lean parturients (group 3, n=25)
Number of subjects: 100
Study 22390465 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory lexical decision task with phonological and semantic manipulation
Number of subjects: 0
Study 19437058 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (30 mL daily)
Number of subjects: 40
Study 19437058 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (30 mL daily)
Number of subjects: 40
Study 19437058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Coconut oil and Soybean oil)
Number of subjects: 40
Study 17296823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 4958
Study 17296823 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 4958
Study 14872552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lescol XL 80 mg once a day for 7 days
Number of subjects: 12
Study 14872552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lescol XL 160 mg once a day for 7 days
Number of subjects: 12
Study 14872552 — intervention group
Group type: COMPARATOR
Intervention: Lescol IR 40 mg twice a day for 7 days
Number of subjects: 12
Study 14872552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lescol XL 80 mg and 160 mg
Number of subjects: 12
Study 14872552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lescol XL 160 mg
Number of subjects: 12
Study 11684539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (glucose)
Number of subjects: 22
Study 11684539 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat drink (safflower oil)
Number of subjects: 22
Study 11684539 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein drink (whey)
Number of subjects: 22
Study 11684539 — intervention group
Group type: COMPARATOR
Intervention: Non-energy placebo
Number of subjects: 22
Study 9839524 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk-supplemented diet (400 mL daily, containing about 109 mg of isoflavones)
Number of subjects: 60
Study 9839524 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 60
Study 9839524 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk-supplemented diet
Number of subjects: 60
Study 7654800 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician referrals from affiliated clinics
Number of subjects: 108
Study 7654800 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and low-cost recruitment methods
Number of subjects: 108
Study 2398199 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.4% hypertonic saline (HS)
Number of subjects: 113
Study 2398199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% polidocanol (POL)
Number of subjects: 113
Study 2398199 — intervention group
Group type: COMPARATOR
Intervention: Both HS and 1% POL
Number of subjects: 113
Study 2398199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% POL (subgroup treatment for TM)
Number of subjects: 113
Study 6778186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tocainide administered over a 15-minute period
Number of subjects: 0
Study 6778186 — intervention group
Group type: COMPARATOR
Intervention: Tocainide over a 24-hour period
Number of subjects: 0
Study 30848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education level
Number of subjects: 204
Study 30848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of foods especially purchased or prepared for IYC
Number of subjects: 204
Study 30848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal care
Number of subjects: 204
Study 30848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum dietary diversity (MDD)
Number of subjects: 204
Study 30848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum meal frequency (MMF)
Number of subjects: 204
Study 30848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum acceptable diet (MAD)
Number of subjects: 204
Study 28364105 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up with written instruction
Number of subjects: 160
Study 28364105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone follow-up)
Number of subjects: 160
Study 28364105 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 160
Study 26001666 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-mind relaxation meditation induction (BMRMI)
Number of subjects: 21
Study 24630487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 75
Study 24630487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 75
Study 22237162 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel (1.23% F) application for 1 min
Number of subjects: 16
Study 22237162 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel (1.23% F) application for 4 min
Number of subjects: 16
Study 22237162 — intervention group
Group type: COMPARATOR
Intervention: No APF application (negative control)
Number of subjects: 16
Study 19444907 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing plasma ferritin levels
Number of subjects: 1634
Study 19444907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron intake
Number of subjects: 1634
Study 17558359 — intervention group
Group type: COMPARATOR
Intervention: Continuous Scale Physical Functional Performance Test (CS-PFP) for nondisabled adults
Number of subjects: 179
Study 17558359 — intervention group
Group type: COMPARATOR
Intervention: Continuous Scale Physical Functional Performance Test (CS-PFP) for individuals with PD
Number of subjects: 179
Study 17558359 — intervention group
Group type: COMPARATOR
Intervention: Continuous Scale Physical Functional Performance Test (CS-PFP) for nondisabled middle-aged individuals
Number of subjects: 179
Study 15194901 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment for ADHD
Number of subjects: 297
Study 15194901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 11598848 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine with aluminum adjuvant
Number of subjects: 0
Study 11598848 — intervention group
Group type: COMPARATOR
Intervention: 11-valent pneumococcal conjugate vaccine without aluminum adjuvant
Number of subjects: 0
Study 9844044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent (ACYW) meningococcal capsular polysaccharide vaccine
Number of subjects: 53
Study 9844044 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-complement-deficient relatives and healthy non-related controls)
Number of subjects: 53
Study 8079927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily for 30 days), tetracycline (500 mg four times daily for 10 days), tinidazol (500 mg three times daily for 10 days)
Number of subjects: 43
Study 8079927 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily for 30 days)
Number of subjects: 43
Study 2647007 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg enprofylline twice daily
Number of subjects: 206
Study 2647007 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg enprofylline twice daily
Number of subjects: 206
Study 2647007 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg enprofylline twice daily
Number of subjects: 206
Study 2647007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 2647007 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg and 300 mg enprofylline
Number of subjects: 206
Study 2647007 — intervention group
Group type: COMPARATOR
Intervention: 150 mg enprofylline and Placebo
Number of subjects: 206
Study 31984531 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger management skills training
Number of subjects: 60
Study 30616984 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-slip-training group (Tt)
Number of subjects: 166
Study 30616984 — intervention group
Group type: COMPARATOR
Intervention: Treadmill-control group (Tc)
Number of subjects: 166
Study 30616984 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-ground-slip training group (Ot)
Number of subjects: 166
Study 30616984 — intervention group
Group type: COMPARATOR
Intervention: Over-ground walking group (Oc)
Number of subjects: 166
Study 28232939 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic group (surgical repair with mesh on the floor of the canal)
Number of subjects: 150
Study 28232939 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal group (surgical repair with mesh under the canal)
Number of subjects: 150
Study 25978688 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration Group (WBVG)
Number of subjects: 38
Study 25978688 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Component Training Group (MTG)
Number of subjects: 38
Study 25978688 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38
Study 23999656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention delivered over 11 one-hour weekly sessions and 2 booster sessions by trained nonspecialists.
Number of subjects: 2512
Study 23999656 — intervention group
Group type: COMPARATOR
Intervention: Standard school curriculum (control group).
Number of subjects: 2512